SPTX outlines Glyph platform progress for oral neuropsychiatric therapies
SPTX presented its neuroscience pipeline, saying the Glyph platform can improve drug bioavailability and safety. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with promising clinical data and upcoming pivotal trials.